Patient Acceptance and Shortened Cycles Paint Optimistic Future For Therapeutic
Vaccine Manufacturers
PR Newswire - April 13, 1998 07:56
%PUB %MTC V%PRN P%PRN
--------------------------------------------------------------------------------
MOUNTAIN VIEW, Calif., April 13 /PRNewswire/ -- Viruses are difficult to
treat because they mutate, rendering initially effective drugs useless against
new viral strains. By targeting only the highly conserved areas of viral
protein, protein-based or deoxyribonucleic acid (DNA) therapeutic vaccines
hope to become the treatment breakthrough patients have been waiting for.
World Therapeutic Vaccines Market, strategic research by Frost & Sullivan
(www.frost.com), studies the market potential for therapeutic vaccines
treating AIDS, cancer and autoimmune diseases. The study spotlights each
disease individually to give an in-depth examination of the discovery,
research and developmental phases of market participants.
The significant acceleration of drug approval by the FDA is very
encouraging to manufacturers in all markets. Through the Prescription Drug
User Fee Act (PDUFA), the FDA collects fees from drug companies to increase
its resources and shorten approval time. The Biotechnology Industry
Organization (BIO) is working with the FDA to formulate PDUFA II that would
mean a further reduction from 27 to 15 months.
Physician and patient acceptance toward therapeutic vaccines is high,
especially for life-threatening illnesses such as AIDS and cancer. Once this
perception is confirmed by clinical trial results, the market for therapeutic
vaccines may expand tremendously as it begins to include patients who
previously would not have considered these alternative treatments.
"In terms of patient populations, the market opportunity is large, but the
types of treatments available on the market will help in defining acceptance
by patients," said Archana Asthana, medical analyst at Frost & Sullivan.
"Often, therapies are not available to the average patient, or are highly
toxic if available. New products could meet with great success, if they can
be effective, accessible and nontoxic."
The first therapeutic vaccine is scheduled to enter the market in 1998 to
treat melanoma cancer. Cancer has received encouragement through clinical
trials from the targeted population, and the long term effects on survival and
recurrence are eagerly awaited. Therapeutic vaccines for breast, stomach and
ovarian cancer are also expected to become available shortly after the turn of
the century.
The positive clinical results from combination triple drug therapy
originally caused a stir among AIDS patients, but this enthusiasm has been
tempered by the eventual drug resistance found in some patients. Researchers
are hoping that The Immune Response Corporation's therapeutic vaccine Remune,
slated for a 1999 release, will provide better long term results.
Key participants in this market include AltaRex Corp., Anergen,
Antigenics, Apollon, Aphton Corporation, Aquila Biopharmaceuticals, AVAX
Technologies, AVI BioPharma, Biomira, CEL-SCI Corporation, Cell Genesys,
Chiron Corporation, Connetics Corporation, Corixa Corporation, Dendreon
Corporation, Epimmune, Genzyme Molecular Oncology, Genzyme Transgenics
Corporation, ImClone Systems, ImmuLogic Pharmaceuticals Corporation, The
Immune Response Corporation, Jenner Biotherapies, LIDAK Pharmaceuticals, Merck
& Co., Pasteur Merieux Connaught, Pangaea Pharmaceuticals, Progenics
Pharmaceuticals, Protein Sciences Corporation, Ribi ImmunoChem Research,
SmithKline Beecham Pharmaceuticals, StressGen Biotechnologies Corporation,
Targeted Genetics Corporation, Therion Biologics Corporation, TRANSGENE,
United Biomedical, VaxGen, and Vical Inc. Companies related to this market
include British Biotech Pharmaceuticals, National Institutes of Health,
University of California San Francisco, and the National Cancer Institute.
This medical industry research has integrated the proven Frost & Sullivan
Market Engineering consulting philosophy into the entire research process.
Critical phases of this research included: identification of industry
challenges, market engineering measurements, strategic recommendations,
planning and market monitoring. All of the vital elements of this system help
the market participants navigate successfully through the therapeutic vaccine
markets.
Frost & Sullivan is an international marketing consulting company that
monitors the medical industry for market trends, market measurements, and
strategies. The ongoing research is utilized to update a series of research
publications such as #5721-52, World Pediatric Vaccine Markets, and to support
industry participants with customized consulting needs.
Visit Frost & Sullivan's web site: frost.com
SOURCE Frost & Sullivan
/NOTE TO EDITORS: Free executive summaries of all Frost & Sullivan
reports are available to the press./
/CONTACT: Keith Hammond of Frost & Sullivan, 650-237-4384, or fax,
650-903-0915, or khammond@frost.com/
/Web site: frost.com |
